Skip to main content
Publications
Hamadani M, Spira AI, Zhou X, Liao L, Chen L, Radford J, Ai WZ, Solh MM, Ardeshna KM, Hess BT, Caimi PF, Stathis A, Carlo Stella C, Alderuccio JP, Kahl BS, Wang Y, Qin YG, Xu ZC, Zinzani PL. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. Blood Adv. 2024 Jan;9(1):93-8. doi: 10.1182/bloodadvances.2023010636
Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jimenez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martinez-Lopez J, Wang Y, Link BK. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022 Nov 22;6(22):5835-43. doi: 10.1182/bloodadvances.2022008150
Ilomaki J, Bell JS, Chan EW, Tolppanen A-M, Luo H, Wei L, Lai EC, Shin J-U, De Paoli G, Pajouheshnia R, Ho FK, Reynolds L, Lau KK, Crystal S, Lau WCY, Man KKC, Brauer R, Chan AYL, Shen C-Y, Kim JH, Lum TYS, Hartikainen S, Koponen M, Rooke E, Bazelier M, Klungel O, Setoguchi S, Pell JP, Cook S, Wong ICK. Application of healthcare 'big data' in CNS drug research: the example of the neurological and mental health global epidemiology network (NeuroGEN). CNS Drugs. 2020 Sep;34(9):897-913. doi: 10.1007/s40263-020-00742-4
Pladevall-Vila M, Pottegard A, Schink T, Reutfors J, Morros R, Poblador-Plou B, Timmer A, Forns J, Hellfritzsch M, Reinders T, Hagg D, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Hallas J, Brandt L, Cortes J, Aguado J, Perlemuter G, Falissard B, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S. Risk of acute liver injury in agomelatine and other antidepressant users in four European countries: a cohort and nested case-control study using automated health data sources. CNS Drugs. 2019 Apr;33(4):383-95. doi: 10.1007/s40263-019-00611-9
Mease P, Gladman D, Davenport E, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naïve subjects with active psoriatic arthritis. Poster presented at the 37th Scandinavian Congress of Rheumatology; September 5, 2018. Helsinki, Finland. [abstract] Scand J Rheumatol. 2018 Sep 5; 47(Suppl 129):34-5. Previously presented at the 2017 ACR/ARHP Annual Meeting.